Molecular Partners AG announced that management will participate in a fireside chat at TD Cowen's 7th Annual Oncology Innovation Summit on May 27, 2026. The clinical-stage biotech company is developing DARPin therapeutics, a novel class of protein drugs, with lead candidate MP0712 progressing in Phase 1/2a trials with initial clinical data expect...

Molecular Partners announced Q1 2026 results with strong financial position (CHF 79 million cash runway until late 2027). The company initiated clinical studies on lead Radio-DARPin MP0712 targeting DLL3 for small cell lung cancer with four clinical sites open and initial data expected in 2026. MP0317 Phase 2 study for cholangiocarcinoma began wi...

Molecular Partners AG announced it will present its lead Radio-DARPin candidate MP0712 at three major scientific conferences in May 2026, including presentations on DLL3-targeting radiotherapy for small cell lung cancer and insights from first-in-human clinical trials.

Molecular Partners announced positive Phase 1 clinical data for MP0317, a tumor-localized CD40 agonist, published in Nature Cancer. The drug demonstrated favorable safety profile and proof-of-mechanism for tumor microenvironment remodeling in advanced cancer patients. An investigator-initiated Phase 2 trial in cholangiocarcinoma combining MP0317 ...

Molecular Partners AG held its Annual General Meeting on April 14, 2026, where shareholders approved all board proposals and elected Clare Fisher, an experienced pharmaceutical executive with over two decades of healthcare leadership, to the Board of Directors. The company also confirmed financial statements showing a net loss of CHF 57.9 million...